– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcom ...

– Unlocks exciting new AI-driven brain biomarker discovery and advancement capabilities – – Substantial processing speed gains while maintaining high signal quality standards – – Comes just months after Firefly announced its acceptance into the NVIDIA Connect Program – KENMORE, Wash. and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcom ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ______________ TO ______________ Commission File Number 001-41092 Firefly Neuroscience, Inc. (Exact name of registrant as specified in its charter) (State or othe ...

Core Insights - Firefly Neuroscience, Inc. is collaborating with Heidelberg University Hospital to study the neurophysiological impact of 15q13.3 copy number variants (CNVs) [1][3] - The study utilizes Firefly's FDA-cleared technology to analyze EEG data from 30 subjects, aiming to uncover insights into brain function related to rare genetic conditions [2][3] - The collaboration reflects a commitment to advancing precision neuroscience and aims to bridge the gap between genotype and phenotype for better patient care [3] Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, with a proprietary technology called Brain Network Analytics (BNA™) [7][8] - The company has built a comprehensive database of brain wave tests over the past 15 years and has achieved FDA clearance for its technology [7][8] - Firefly is targeting pharmaceutical companies and medical practitioners for the commercial launch of its BNA™ technology [7] Study Objectives - The study aims to identify electrophysiological biomarkers associated with 15q13.3 CNVs [6] - It will characterize neurocognitive profiles linked to deletions versus duplications of the chromosomal region [6] - The research supports future diagnostic and therapeutic strategies for neurodevelopmental disorders [6]

– Comes less than a year after listing on Nasdaq – KENMORE, N.Y., June 23, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced that it will be added to the Russell Microcap® Index as part of this year’s reconstitution. The additions will be made effective after the U.S. market opens on Ju ...

Core Insights - Firefly Neuroscience, Inc. has made significant advancements in Alzheimer's research, focusing on differentiating between subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia through accessible diagnostic methods [1][2] Group 1: Research Findings - The combination of EEG/ERP and volumetric magnetic resonance imaging (vMRI) provides the most accurate results for diagnosing cognitive impairments, achieving an accuracy of approximately 87% (AUC=0.87) when both methods are used together [2] - Key EEG measures identified include reaction time, commission errors, and P300b amplitude, which alone can categorize subjects with around 80% accuracy (AUC=0.79) [2] - The left temporal lobe size is a significant MRI predictor of cognitive issues, with smaller sizes correlating to higher cognitive impairment [2] Group 2: Company Developments - Firefly's recent acquisition of Evoke Neuroscience has enabled the integration of research teams to leverage a proprietary database of over 180,000 standardized EEG/ERP assessment records [3] - The company is working to link its breakthrough cognitive brain age biomarker with the findings from the recent study, aiming for a proactive approach to early screening and staging of Alzheimer's disease [3] - Firefly's FDA-cleared Brain Network Analytics (BNA™) technology is set to revolutionize diagnostic and treatment monitoring methods for various neurological and mental disorders [4][5] Group 3: Market Position and Strategy - Firefly targets pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical use of its BNA™ technology [4] - The company has built a comprehensive database of brain wave tests over the past 15 years, securing patent protection and achieving FDA clearance for its technologies [4][5]

Product Development and Launch - The BNA Platform has been developed using AI and includes a database of over 18,000 patients, focusing on twelve disorders[78] - The company plans to commercially launch the BNA Platform in 2025, with no expected material additional development costs[79] - The company aims to enhance patient outcomes through the BNA Platform by establishing objective baseline measurements of brain function[82] - The company expects to incur significant costs for at least two to four years to commercialize and distribute its flagship product, the BNA Platform[102] Financial Performance - Revenue for the three months ended March 31, 2025, was $43,000, compared to $12,000 for the same period in 2024, representing an increase of $31,000 or 258%[96] - Research and development expenses increased to $312,000 for the three months ended March 31, 2025, from $289,000 in 2024, an increase of $23,000 or 8%[97] - Selling and marketing expenses decreased to $208,000 in Q1 2025 from $249,000 in Q1 2024, a decrease of $41,000 or 16%[98] - General and administration expenses rose significantly to $1,588,000 in Q1 2025 from $565,000 in Q1 2024, an increase of $1,023,000 or 181%[99] - Other income (expense) for the three months ended March 31, 2025, was $(10,865,000), compared to $(31,000) in 2024, representing an increase in expenses of $10,834,000[100] - Net cash used in operating activities was $(2,511,000) for Q1 2025, compared to $(1,319,000) in Q1 2024, an increase of $1,192,000 or 90%[107] - Net cash provided from financing activities was $10,253,000 in Q1 2025, compared to $945,000 in Q1 2024, an increase of $9,308,000 or 985%[109] Acquisitions and Financing - On April 30, 2025, the company acquired Evoke Neuroscience, Inc. for approximately $6 million, consisting of $3 million in cash and 857,149 shares valued at $3.50 each[84] - The company acquired all outstanding stock of Evoke for approximately $6,000,000, consisting of $3,000,000 in cash and 857,142 shares of common stock[101] - The company has no committed source of financing and may not be able to raise funds as needed to continue operations[113] Operational Expenses - Research and development expenses are expected to continue to be the largest component of operating expenses as the company updates and maintains the BNA Platform[88] - Selling and marketing expenses include employee-related costs and consulting fees, which are expected to increase as the company expands its market presence[89] - General and administrative expenses will rise due to compliance with SEC and Nasdaq regulations, as well as other public company-related costs[90] Revenue Generation Strategy - Revenue generation will focus on two segments: use of the BNA Platform by neurologists in the U.S. and collaborations with pharmaceutical companies[87] Capital Raising Activities - A private placement agreement was entered into on March 28, 2025, to issue 547,737 units at a price of $3.00 per unit[86] - The company received total proceeds of $8.825 million from the exercise of warrants to purchase 1,623,530 shares of common stock[85]

Evoke的首席执行官兼首席科学官David Hagedorn博士表示，"Evoke和Firefly之间可以产生商业协同效 应，我们将携手合作，建立一个强大且不断发展的业务。" Firefly Neuroscience 的首席执行官Greg Lipschitz说，" BNA ™ 数据库在每一次新的 临床研究和/或临床评估中不断扩展，我们相信收购Evoke是 Firefly Neuroscience实现其目标的关键一 步， 建立世界上第一个基于EEG/ERP的人类大脑基础模型 。" # 3天上涨近400% 报名：首届全球心血管大会 | 最新议程 合作伙伴征集：2025全球手术机器人大会 2025年5月5日， Firefly Neuroscience （纳斯达克股票代码：AIFF）宣布收购 Evoke Neuroscience ，后者是一家创新医疗器械公司，主要开发和商业化用于辅助全面评估大脑健康的技术。此次交易标志着 Firefly Neuroscience朝着利用脑网络分析（ BNA ™ ） 技术构建专有的人脑基础模型迈出了重要一步。 # 收购详情 收购条款包括 支付 600万美元 （约合人民币 4336万） ...

Core Insights - Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., enhancing its proprietary database, intellectual property portfolio, and commercial footprint significantly [1][2] - The acquisition is expected to facilitate the development of a foundation model of the human brain using Firefly's FDA-cleared Brain Network Analytics (BNA™) technology [1][2] Company Overview - Firefly Neuroscience, Inc. (NASDAQ: AIFF) focuses on developing AI solutions aimed at improving brain health outcomes for patients with neurological and mental disorders [3] - The company has built a comprehensive database of brain wave tests and secured patent protection over the past 15 years, with its BNA™ technology revolutionizing diagnostic methods for various mental health conditions [3][4] Acquisition Details - The acquisition of Evoke Neuroscience will result in a more than two-fold increase in proprietary brain scans, a three-fold increase in patents, and a ten-fold increase in commercial sites [2] - The purchase terms include a total payment of $6 million, split 50% in cash and 50% in Firefly's common stock priced at $3.50 per share, along with a potential earn-out of $500,000 for Evoke's investors [4] Technological Synergies - The combined resources of Firefly and Evoke are expected to create significant technological, clinical, and commercial synergies, enhancing the capabilities of both companies [2] - Firefly's BNA™ technology, developed using AI and machine learning, utilizes a large proprietary database of standardized EEGs to provide comprehensive insights into brain function [4][5] Market Position - Firefly targets pharmaceutical companies involved in drug research and clinical trials, as well as medical practitioners for clinical use, positioning itself as a leader in brain health diagnostics [3][4]

Core Insights - Firefly Neuroscience, Inc. has acquired Evoke Neuroscience, Inc., marking a significant step towards developing a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology [1][2]. Company Overview - Firefly is an AI company focused on improving brain health outcomes for patients with neurological and mental disorders, utilizing its BNA™ technology for diagnostics and treatment monitoring [3][4]. - The company has built a comprehensive database of brain wave tests and secured patent protection over the past 15 years, now targeting pharmaceutical companies and medical practitioners for commercial use [3]. Acquisition Details - The acquisition of Evoke will enhance Firefly's assets, including a more than two-fold increase in proprietary brain scans, a three-fold increase in patents, and a ten-fold increase in commercial sites [2]. - The purchase terms include a total payment of $6 million, split 50% in cash and 50% in Firefly's common stock priced at $3.50 per share, along with a potential $500,000 earn-out for Evoke's investors based on future revenue performance [5]. Technological Synergies - The integration of Evoke's technologies is expected to create significant technological, clinical, and commercial synergies, enhancing Firefly's capabilities in brain health assessment [2]. - Firefly's BNA™ technology utilizes AI and machine learning on a proprietary database of over 17,000 patients, providing comprehensive insights into brain function and improving diagnostic accuracy for mental and cognitive disorders [4]. Market Position - Firefly possesses the largest known proprietary database of over 180,000 standardized EEG/ERP assessment records and has 27 granted patents, positioning the company strongly in the brain health technology market [5].